Research coverage runs from preclinical mechanism papers to AI-driven peptide discovery. Most of what shows up here lives in Nature, Cell, Science, JAMA, and the abstracts from AACR, ESCMID, AAN, and ESCMID Global.
A few threads keep recurring. Macrocyclic and bicyclic peptides keep getting better at hitting "undruggable" targets — KRAS, beta-catenin, intracellular protein–protein interactions. Antimicrobial peptides have moved from theory to clinical candidates against carbapenem-resistant organisms and biofilms. Cancer peptide vaccines (ELI-002, autogene cevumeran, EVX-01) are producing real survival data. AI design tools — protein language models, transformer architectures, de novo platforms — are starting to generate hits that humans wouldn't.
If you want the lab side without the press releases, this is the right surface. The stories below name the lab, the journal, and the result.
A new Nature Biomedical Engineering paper introduces HMD-AMP, a protein language model-based approach that outperforms prior methods at identifying evolutionarily distant antimicrobial peptides. Applied to host and gut microbiome genomes of nine mammals, HMD-AMP revealed over 37 million predicted AMPs. Of 91 experimentally validated high-confidence sequences, 74 showed strong antibacterial activity and 48 were evolutionarily remote from known AMPs, including four with broad-spectrum activity at low toxicity.
A study published in Medical Xpress analyzed 5,741 days of AI-powered dietary-tracking data from 332 adults with overweight or obesity. GLP-1 users consumed significantly less energy (1,102 vs 1,281 kcal/day) and protein (53.8 vs 62.0 g/day) than non-users. Weight-adjusted daily protein intake was 0.6 g/kg/day among GLP-1 users, with 88% falling below the Italian national 0.9 g/kg/day recommendation. IRCCS San Raffaele researchers warn of nutritional deficiencies and muscle-health risks during GLP-1 therapy.
Richard DiMarchi and Matthias Tschöp — whose work enabled Eli Lilly's Zepbound and the modern GLP-1 class — published a peer-reviewed draft paper arguing that targeting GIP and glucagon receptors alone, without GLP-1, may deliver comparable weight loss without the nausea and vomiting that plague current therapies. The experimental molecule, backed by BlueWater Biosciences, challenges the central dogma of obesity drug design. Results are preclinical and must still translate to humans.
Omada Health published results from a 12-week study of 245 adults with obesity comparing its GLP-1 Care Track behavioral program (151 members) to a control group (94). Omada members lost 1.8x more total weight (6.0% vs 3.3% of starting weight), 2.1x more body fat, and saw increased muscle mass percentage and improved mental health scores. The finding directly addresses sarcopenia concerns highlighted in recent NPR coverage of GLP-1 discontinuation.
A Nature Communications paper introduces CAMPER (Constraint-driven AMP Engineering with Ranking), a mechanistic AI framework that integrates machine learning with biophysical ranking to design membrane-targeting peptides against MRSA persisters and biofilms. The framework identified WP-CAMPER1, a 12-mer peptide that kills S. aureus MW2 at an MIC of 4 µg/mL; a 2% topical formulation reduced S. aureus burden by 2.5 log10 in a murine skin infection model.
Researchers at Toronto's Sinai Health published in Cell Metabolism that semaglutide acts directly on liver sinusoidal endothelial cells (LSECs) to reverse MASH independently of weight loss. Although LSECs account for only ~3% of liver cell volume, they are the key driver of hepatoprotection. Semaglutide reversed MASH in mice lacking brain appetite receptors, while mice lacking LSEC receptors saw no liver improvement despite losing 20% body weight.
A Cell Reports Medicine study presenting four preclinical experiments and a proof-of-concept clinical trial reports that GLP-1 medicines predominantly reduce body fat alongside a small but significant decrease in lean body mass in obese mice and humans. Among lean tissues, loss of liver mass exceeds change in muscle mass, and while absolute muscle mass and strength decrease, relative muscle mass and strength improve — translating into better running performance in mice.
A Nature Communications paper describes peptide dendron nanoassemblies that shape-shift in response to bacterial enzymes to eradicate intracellular drug-resistant bacteria while protecting host macrophages. The nanoassemblies combine self-assembling regions, cell-penetrating motifs, enzyme-responsive sequences, and integrin-targeting ligands, transforming from nanoparticles to nanofibers for prolonged cell retention before converting back to nanoparticles for cellular uptake.
A team at Kumamoto University led by Associate Professor Shingo Ito developed a cyclic peptide (D-DNP-V) that ferries insulin across the small intestine. Combined with zinc-stabilized insulin hexamers and given orally to diabetes models, the platform rapidly normalized blood sugar with once-daily dosing for three consecutive days. A click-chemistry-conjugated DNP-insulin molecule performed equivalently, substantially reducing the high doses that have historically plagued oral insulin.
A Nature Communications paper published April 15 reveals shared structural mechanisms between SbmA — an E. coli membrane transporter that imports antimicrobial peptides — and ABC transporters. Using cryo-electron microscopy, EPR spectroscopy, and molecular dynamics simulations, researchers demonstrated SbmA undergoes ABC-transporter-like conformational changes, informing strategies to design antibiotic-resistant-bacteria-penetrating peptide drugs.
An NPR investigation found fewer than 1 in 4 patients stay on GLP-1 medications after a year, with most planning to restart later. Researchers warn that up to 40% of weight lost on GLP-1s is lean muscle, and cycling on and off the drugs may accelerate sarcopenia. When patients stop, fat regains rapidly while muscle recovery is uncertain.
A systematic review and meta-analysis in The American Journal of Medicine analyzing collagen peptide supplements found significant improvements in skin elasticity, hydration, and wrinkles — but only in industry-funded and low-quality studies. High-quality studies and those without pharmaceutical funding showed no significant effect across all categories.
A comprehensive review in Discover Oncology highlights antimicrobial peptides' emerging dual role as anticancer and antiviral therapeutics. AMPs selectively target cancer cell membranes through electrostatic interactions while also demonstrating antiviral activity, with their immunomodulatory properties and reduced resistance development offering advantages over conventional chemotherapy.
University of Birmingham researchers showed that the naturally occurring immunopeptide PEPITEM reduced inflammatory arthritis joint swelling comparably to infliximab in preclinical models — but without the immunosuppressive side effects. Published in Arthritis & Rheumatology, the findings suggest PEPITEM could reduce early-stage reliance on steroids in rheumatoid and psoriatic arthritis.
A study in Nature Microbiology used a generative protein language model (ProteoGPT) to discover novel antimicrobial peptides effective against multidrug-resistant bacteria. The AI-designed peptides showed comparable or superior efficacy to clinical antibiotics in mouse infection models, with reduced resistance development and no organ damage.
A new phage display platform using ~482 venom-derived peptide scaffolds and machine learning-guided mutation design achieved a 100% success rate identifying strong binders across four diverse therapeutic targets (CD47, DLL3, IL33, P2X7R). The approach could accelerate venom peptide drug discovery for cancer, inflammation, and pain.
A comprehensive review in Frontiers in Drug Delivery examines the barriers to oral peptide bioavailability — enzymatic degradation, poor membrane permeability, and first-pass metabolism — and maps emerging solutions including permeation enhancers, nanoparticle encapsulation, mucoadhesive systems, and microRNA-based approaches that are advancing toward clinical translation.
Stanford scientists used AI to identify BRP, a naturally occurring peptide that acts directly on the hypothalamus to suppress appetite — avoiding the gut-related side effects of current GLP-1 drugs. In animal studies, BRP reduced body weight and fat without nausea, constipation, or muscle loss. Published in Nature, with human trials planned.